. Author manuscript; available in PMC: 2013 Aug 1.

Published in final edited form as: Invest New Drugs. 2011 Jul 29;30(4):1614–1620. doi: 10.1007/s10637-011-9708-3

Table 2.

Overall Survival¹ and Time to Progression¹

Median Overall Survival (OS)	101 days (range 19–506) CI=(57–151)
Time to Progression (TTP)	42 days (range 14–104) CI=(22–49)

Overall survival and time to progression in evaluable patients, n=19